CTOs on the Move

Institute for Clinical Evaluative Sciences

www.ices.on.ca

 
Institute for Clinical Evaluative Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ices.on.ca
  • 2075 Bayview Ave
    Toronto, ON CAN M4N 3M5
  • Phone: 416.480.6100

Executives

Name Title Contact Details

Similar Companies

Aspect DV

Aspect DV is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

C2i Genomics

C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.

Bioneer

Bioneer is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lamination Technologies Inc

Lamination Technologies Inc is a Freeport, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Botanix Pharmaceuticals

Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.